Is NCT07003997 recruiting in Atlanta, GA?

Yes, NCT07003997 is currently recruiting participants at its Atlanta, GA location. This major depressive disorder clinical trial is actively enrolling qualified participants.

How do I join the major depressive disorder clinical trial in Atlanta?

To join this clinical trial in Atlanta, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Atlanta clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Major Depressive Disorder Clinical Trial in Atlanta, GA

About This Major Depressive Disorder Study in Atlanta

This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.

Sponsor: Emory University

Who Can Participate

Inclusion Criteria

willing and able to give written informed consent;

men or women, 25-55 years of age;

a primary diagnosis of DSM-V major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V;

score of \>14 on the PHQ-9 from screening and HAM-D score ≥18 for study entry;

off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine),

CRP ≥3 mg/L,

PHQ-9 anhedonia score ≥2.

Exclusion Criteria

history or evidence (clinical and laboratory) of an autoimmune disorder

history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection;

history of any type of cancer requiring treatment with more than minor surgery;

unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing);

significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000)

history of progressive multifocal leukoencephalopathy,

history of deep venous thrombosis,

history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK),

major surgery within 8 weeks prior to screening or will require major surgery during the study,

current or recent (\<4 weeks prior to randomization) viral (including COVID-19), bacterial, fungal, or parasitic infection or any other active or recent infection,

symptomatic herpes zoster infection at or within 12 weeks of randomization,

history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement),

cirrhosis of the liver from any cause,

any of the following specific abnormalities on screening laboratory tests: ALT or AST \>2 x upper limits of normal (ULN), alkaline phosphatase (ALP) ≥2 x ULN, total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \<2 x ULN),

chronic kidney disease with eGFR \<60 mL/min/1.73 m2,

history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview);

active suicidal plan as determined by a score \>3 on item #3 on the HAM-D; g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms);

history of a cognitive disorder or traumatic head injury involving loss of consciousness;

pregnancy or lactation,

use of gender affirming hormone therapy;

chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), immunosuppressive (e.g., biologics), glucocorticoid containing medications or minocycline within 6 months, or non-prescription supplements with known or suspected anti-inflammatory properties (e.g. fish oil supplements) within 2 weeks of baseline, or at any time during the study;

any contraindication for MRI scanning;

failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime; and

BMI \>45 (to exclude severe obesity) or at the PI's discretion based on the patient's ability to fit comfortably in the MRI scanner.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT07003997) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Major Depressive Disorder Treatment Options in Atlanta, GA

If you're searching for major depressive disorder treatment options in Atlanta, GA, this clinical trial (NCT07003997) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all major depressive disorder clinical trials near you to find additional studies recruiting in your area.

Major Depressive Disorder Clinical Trial in Atlanta, GA

Expert Care in Atlanta

IRB Approved

No-Cost Care

Apply for This Atlanta Location

Why Participate?

Simple Process